Human Vascular Endothelial cell Growth Factor C,VEGF-C ELISA KIT

Instructions
Code CSB-E04759h
Size 96T,5×96T,10×96T
See More Details 24T ELISA kits trial application
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Target Name vascular endothelial growth factor C
Alternative Names Flt 4L ELISA Kit; Flt4 ligand ELISA Kit; FLT4 ligand DHM ELISA Kit; Flt4-L ELISA Kit; Flt4L ELISA Kit; Vascular endothelial growth factor C ELISA Kit; Vascular endothelial growth factor related protein ELISA Kit; Vascular endothelial growth factor-related protein ELISA Kit; VEGF C ELISA Kit; VEGF-C ELISA Kit; Vegfc ELISA Kit; VEGFC_HUMAN ELISA Kit; VRP ELISA Kit
Abbreviation VEGFC
Uniprot No. P49767
Species Homo sapiens (Human)
Sample Types serum, plasma, tissue homogenates
Detection Range 15.6 pg/mL-1000 pg/mL
Sensitivity 3.9 pg/mL
Assay Time 1-5h
Sample Volume 50-100ul
Detection Wavelength 450 nm
Research Area Cancer
Assay Principle quantitative
Measurement Sandwich
Precision
Intra-assay Precision (Precision within an assay): CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV%<10%
Three samples of known concentration were tested in twenty assays to assess.
Linearity
To assess the linearity of the assay, samples were spiked with high concentrations of human VEGF-C in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
 SampleSerum(n=4)
1:1Average %100
Range %96-105
1:2Average %92
Range %87-99
1:4Average %95
Range %90-101
1:8Average %92
Range %88-96
Recovery
The recovery of human VEGF-C spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample TypeAverage % RecoveryRange
Serum (n=5) 9994-106
EDTA plasma (n=4)9084-96
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
pg/mlOD1OD2AverageCorrected
10002.575 2.543 2.559 2.446
5001.880 1.776 1.828 1.715
2501.051 1.034 1.043 0.930
1250.613 0.587 0.600 0.487
62.50.387 0.371 0.379 0.266
31.20.235 0.226 0.231 0.118
15.60.169 0.158 0.164 0.051
00.115 0.111 0.113  
Troubleshooting
and FAQs
ELISA kit FAQs
Storage Store at 2-8°C. Please refer to protocol.
Lead Time 3-5 working days

Target Data

Function Growth factor active in angiogenesis, and endothelial cell growth, stimulating their proliferation and migration and also has effects on the permeability of blood vessels. May function in angiogenesis of the venous and lymphatic vascular systems during embryogenesis, and also in the maintenance of differentiated lymphatic endothelium in adults. Binds and activates KDR/VEGFR2 and FLT4/VEGFR3 receptors.
Gene References into Functions
  1. A possible mechanism has been proposed of the TGF-beta-VEGF-C pathway in which TGF-beta promotes VEGF-C production in tubular epithelial cells, macrophages, and mesothelial cells, leading to lymphangiogenesis in renal and peritoneal fibrosis. (Review) PMID: 30142879
  2. The mutation induced skipping of exon 2 of VEGFC resulting in a frameshift and the introduction of a premature stop codon (p.Ala50ValfsTer18). The mutation leads to a loss of the entire VEGF-homology domain and the C-terminus. PMID: 30071673
  3. VEGFR-3 and CAV3 expression demonstrated immunohistochemically in SMCs of the tunica media of SV grafts predicted their early restenosis in triple-vessel CAD patients. CAV2 protein expression in SMCs of ITA grafts indicated the risk of early graft failure both in double-vessel and triple-vessel CAD subjects. PMID: 29557990
  4. VEGF-C expression and secretion in gastric cancer is downregulated by kallistatin. PMID: 29243194
  5. Concomitant high expression of survivin and VEGF-C is closely associated with LNM status of PTC patients, which suggests their cooperation in the metastatic process. PMID: 29578160
  6. TNFSF15, a cytokine mainly produced by blood endothelial cells, facilitates tumor lymphangiogenesis by upregulating VEGFC expression in A549 cells. PMID: 29890027
  7. serum levels not elevated in patients with erythrodermic mycosis fungoides/Sezary syndrome PMID: 28925057
  8. SPARC expression was inversely associated with the degree of malignancy and it had a negative correlation with VEGF-C and VEGF-D expression. Results suggest SPARC might function as a tumor suppressor inhibiting angiogenesis and lymphangiogenesis in ovarian cancer by reducing the expression of VEGF-C and VEGF-D. PMID: 29075785
  9. VEGF-A/VEGF-C analysis showed higher positivity in metastatic nodes and higher positivity in the surrounding negative nodes from positive cases in comparison with nonmetastatic patients. PMID: 28984690
  10. this study shows that decidual NK cells facilitate the interaction between trophoblastic and endothelial cells via VEGF-C and HGF PMID: 28653669
  11. Lymphangiogenesis during tubulointerstitial fibrosis to be associated with increased expression of CTGF and VEGF-C in human obstructed nephropathy as well as in diabetic kidney disease. vitro, CTGF induced VEGF-C production in HK-2 cells, while CTGF siRNA suppressed transforming growth factor beta1-induced VEGF-C upregulation. PMID: 28545716
  12. study is the first to describe the mechanism of leptin-promoted lymphangiogenesis by upregulating VEGF-C expression in chondrosarcomas. PMID: 27345723
  13. Retroperitoneal tumour progression in EOC patients is associated with high VEGF-C expression. PMID: 28591727
  14. Mechanistic investigations indicated that BDNF facilitated VEGF-C-dependent lymphangiogenesis through the MEK/ERK/mTOR signaling pathway. PMID: 28771226
  15. Results has shown that VEGF-C was highly expressed in non-small cell lung cancer (NSCLC) tissues and metastatic lymph nodes. VEGF-C expression levels was significantly correlated with lymph node metastasis in NSCLC. Along with CXCR4, VEGF-C might synergically promote lymphatic metastasis in lung cancer and might be a clinical predictor of lymph node metastasis in NSCLC patients. PMID: 28925100
  16. CXCR4, CCR7, VEGF-C and VEGF-D expression might have synergistic effects on the lymph node metastasis in patients with cervical cancer. PMID: 28535405
  17. prolactin induction of VEGF-C and Runx2 was inhibited partly by Carboxypeptidase-D inhibitors, implicating nitric oxide , produced by PRL-regulated Carboxypeptidase-D, in breast cancer progression PMID: 28364216
  18. Study is the first to describe the mechanism of bFGF-promoted lymphangiogenesis by upregulating VEGF-C expression in chondrosarcomas. PMID: 27229532
  19. eIF4E promoted cholangiocarcinoma cell metastasis by up-regulating the expression of VEGF-C, MMP-2 and suppressing E-cadherin expression. PMID: 27907907
  20. High expression of VEGF-C in the primary tumour may be a good determinant for detection of occult tumour cells in the lymph nodes of OSCC cases. PMID: 27417330
  21. document for the first time that CCL5 induces tumor lymphangiogenesis by the induction of VEGF-C in human cancer cells. PMID: 27166194
  22. Data suggest that the BRG1/STAT3/VEGFC in tumor-associated lymphangiogenesis might lead to the discovery of novel therapeutic targets in the treatment of cancers with BRG1 loss of function. PMID: 27145366
  23. Studied the effect of recombinant human vascular endothelial growth factor (VEGF)-C on lymphangiogenesis, inflammation, and fibrosis in the mouse kidney using the unilateral ureteral obstruction (UUO); lymphangiogenesis was significantly induced in the UUO+VEGF-C group. In lymphatic endothelial cells, VEGF-C increased the activity and proliferation of such cells and expression of VCAM-1. PMID: 29083411
  24. This study reports that human dendritic cells produce VEGF-C, a cytokine with potent pro-lymphangiogenic activity when stimulated with IFN-gamma PMID: 26987844
  25. Association of coexpressed high levels of VEGF-C and active MMP-9 with lymphatic spreading and local invasiveness of Papillary thyroid carcinoma (PTC) suggests their potential usefulness as predictive biomarkers of aggressive PTC behavior. PMID: 27806941
  26. Data show that VEGF-C, VEGF-D, and VEGFR-3 were expressed in a substantial percentage of breast carcinomas. PMID: 28791841
  27. By treating LECs with VEGF-C156S and analyzing subsequent changes in gene expression, we identified several 'immediate early' transcription factors that showed a rapid transient upregulation VEGFR-3 stimulation. these results reveal an important and unanticipated role of HOXD10 in the regulation of VEGFR-3 signaling in lymphatic endothelial cells, and in the control of lymphangiogenesis and permeability. PMID: 27199372
  28. In colon cancer samples, there was a positive correlation between the expression of integrin alpha4 and VEGF-C. Integrin alpha4 and VEGF-C were significantly associated with the clinicopathological parameters (LMVD, Duke's stage, and lymph node metastasis). patients with high integrin alpha4 or VEGF-C expression had significantly shorter overall survival and tumor-free survival time. PMID: 26917449
  29. High VEGFC expression is associated with angiogenesis and lymphangiogenesis. PMID: 27852824
  30. Adiponectin promoted VEGF-C expression and secretion in human chondrosarcoma cells. PMID: 27252405
  31. Study showed that VEGF-C levels are high in hypervolemic and low in euvolemic (and hypovolemic) chronic kidney disease patients; serum VEGF-C levels were significantly correlated with bioimpedance spectroscopy measurements PMID: 28471955
  32. Taken together, we suggest that ELK3 is an upstream regulator of the NF-kappaB signaling pathway, the inhibition of which leads to the suppression of peritumoral lymphatic vessel development, possibly due to a low VEGFC expression. PMID: 28188790
  33. These results indicate that VEGF-C-induced MSC osteogenesis is mediated through VEGFR2 and VEGFR3, and followed the activation of the ERK/RUNX2 signaling pathway. PMID: 28163024
  34. Overexpression of vascular endothelial growth factor C (VEGF-C) in Kazakh esophageal squamous cell carcinoma (ESCC) was significantly associated with gender, depth of tumor invasion, lymph node metastasis and tumor clinical stage. PMID: 27939650
  35. This paper quantifies the lymphatic microvessel density (LMD) in benign and malignant salivary gland tumors and analyzes the relationship between LMD and tumor expression of vascular endothelial growth factors C (VEGF-C) and the proliferative index. PMID: 27229879
  36. KAI1-induced decreases in VEGFC expression are mediated via Src/STAT3 signaling pathways in pancreatic cancer cells. PMID: 27082851
  37. The results of this study suggest that the more aggressive biological behavior of squamous cell carcinoma of the tongue in young patients may be related to a higher expression of VEGF-C. PMID: 27876236
  38. This study suggests that NRP1 expression and LVD are independent factors that are likely to predict the risk of LN metastasis in squamous cell carcinoma (SCC)of the tongue, whereas the expression of VEGFC, VEGFR3, CCR7, and SEMA3E are nonindependent predictive factors PMID: 27666723
  39. High expression of VEGFC is associated with peritoneal dissemination in gastric cancer. PMID: 26621525
  40. TNF-alpha mediates VEGF-C expression, which plays a critical role in the pathogenesis of pterygia. PMID: 27314284
  41. a potential link between the upregulation of Syk and VEGF-C expression and lung adenocarcinoma. PMID: 27461624
  42. The summarizes the structure and function features of pathway-related molecules of VEGFC/D-VEGFR3/NRP2 axis, stages of various tumors and their molecular mechanisms and significances in tuthe expression changes of these molecules in different anatomic organs or histopathologic types or development lymphatic metastasis. PMID: 27527412
  43. Data show that WNT1-inducible signaling pathway protein-1 (WISP)-1/CCN4 expression was correlated with vascular endothelial growth factor-C (VEGF-C) expression in Oral squamous cell carcinoma (OSCC) specimens. PMID: 26824419
  44. VEGF-C overexpression shows an unfavorable prognosis for EC patients. PMID: 27540974
  45. FIGO stage (P < 0.0001), tumor grade (P < 0.0001), lymph node metastasis (P < 0.0001), serum VEGF-C concentration (P = 0.0001), and ascites VEGF-C concentration (P < 0.0001) were significantly correlated with overall survival in ovarian cancer. PMID: 23473018
  46. Our data suggested that IL-6 mediates the singnal pathway of JAK-STAT3-VEGF-C promoting the growth, invasion and lymphangiogenesis in gastric cancer PMID: 26750536
  47. The most extensively accepted signaling pathways promoting lymphangiogenesis in tumors include the secreted lymphangiogenic proteins: VEGF-C and VEGF-D, and their cognate receptor on lymphatic endothelium VEGF receptor-3 (VEGFR-3). PMID: 26706909
  48. the concurrent high expression of VEGF-C and NRP2 is predictive of the unfavorable prognosis in glioblastoma. PMID: 26753562
  49. a significant decrease in miR101 levels, accompanied with an increased expression of vascular endothelial growth factor (VEGF)C in cisplatinresistant SGC7901 gastric cancer cells. PMID: 26573417
  50. MTA1 is up-regulated in CRC; its expression is inversely associated with lymphatic metastases and the expression of VEGFC, VEGFD and VEGFR3 PMID: 26543080
  51. miR-27b, miR-101 and miR-128 inhibit angiogenesis by down-regulating VEGF-C expression in gastric cancers. PMID: 26460960
  52. VEGF-C/D score correlated neither with peypher lymphatic vessel density (LVD) nor with LVD in the tumor center PMID: 26296919
  53. study suggests that both VEGF-C and VEGF-D in tumor cells promote lymph node metastasis PMID: 25911567
  54. Immunohistochemical analysis of 122 gliomas showed that TGLI1 expression was positively correlated with VEGF-C, TEM7 and microvessel density. PMID: 26093087
  55. PKM2 expression was correlated with VEGF-C expression, and combination of PKM2 and VEGF-C levels had the better prognostic significance in predicting the poor outcome of patients with breast cancer. PMID: 26339369
  56. Serum levels of VEGF-C do not appear to predict sentinel lymph node status in patients with early breast cancer who undergo SLNB. PMID: 26104766
  57. Findings suggest that ILT4 drives NSCLC development in part on activation of ERK signaling which in turn upregulates VEGF-C. PMID: 25948790
  58. There was evidence that HMGB1 upregulates VEGF-C by activating NF-kappaB in a colon cancer cell line. PMID: 26001393
  59. Inhibition of COX-2 activity reduced VEGF-C mRNA expression and secretion in cholangiocarcinoma cells and decreased their migration but not proliferation PMID: 26125824
  60. Our data suggest that Hodgkin and Reed-Sternberg cells produce VEGFC, and VEGFC expression could be a novel prognostic factor in cHL. PMID: 25098430
  61. high podoplanin expression is associated with aggressive tumor behavior, poor prognosis and metastatic regulation through interaction with VEGF-C. PMID: 26081937
  62. Data indicate that microRNA miR-101 negatively regulates vascular endothelial growth factor C (VEGF-C) protein expression post-transcriptionally. PMID: 25658842
  63. VEGF-C plays a crucial role in tumor lymphangiogenesis and lymph node metastasis of ovarian cancer. PMID: 26443563
  64. VEGF-C inhibition reverses resistance of bladder cancer cells to cisplatin via upregulating maspin. PMID: 25936422
  65. In salivary adenoid cystic carcinoma cells, WIP1 silencing reduced VEGF-C expression. Overexpression of VEGF-C restored migration and invasion in WIP1 knockdown cells. PMID: 25797250
  66. Both VEGF-C and MMP13 are significantly upregulated in Multiple Myeloma with lymph-node metastases. PMID: 25966777
  67. These findings suggest that IL-8 may be a potent inducer of LECs, although this effect does not appear to involve the VEGF-C/VEGF-D and VEGFR-3 signaling pathway. PMID: 25891418
  68. TNFR1 has a role in mediating TNF-alpha-induced tumour lymphangiogenesis and metastasis by modulating VEGF-C-VEGFR3 signalling PMID: 25229256
  69. The results of the meta-analysis strongly indicate that VEGF-C expression could function as a marker for predicting the aggressiveness and prognosis of ESCC. PMID: 25792082
  70. The preoperative sVEGF-C/D levels might be reliable biomarkers for the presence of disease and LNM in patients with GBC. The sVEGF-C/D levels may be prognosis factors that can predict a poor outcome for GBC patients PMID: 25801241
  71. Significant associations were found between VEGFC tag SNPs (individually and within haplotypes) and the presence of any DR or DME in white participants with T1DM and T2DM. PMID: 26072347
  72. Both VEGF-C and VEGF-D are highly expressed in esophageal squamous cell cancer tissue, which may be related to the lymph node metastasis of cancer cells. PMID: 25640364
  73. These finding suggest that VEGF-C upregulated cortactin expression through Src-mediated downregulation of miR-326. PMID: 25212831
  74. VEGFC and VEGFR1 mRNA overexpression is of prognostic value, dependent on HER2 status. PMID: 26124351
  75. analysis of PDGFR, VEGF-C, and proteins of the mToR pathway before and after androgen deprivation therapy in prostate carcinoma PMID: 24243494
  76. High expression of VEGF-C is associated with atherosclerotic arteries. PMID: 25318003
  77. This mini-review will focus on summarizing recent discoveries regarding the unconventional functions of VEGF-C in cancer progression PMID: 25888649
  78. Expression of vascular endothelial growth factor C is related to tumor invasion and lymphatic invasion and is not related to lymph node micrometastasis in patients with pN0 esophageal squamous cell carcinoma. PMID: 26176055
  79. VEGFC signaling via VEGFR3 promotes lymphangiogenesis and metastasis by orthotopic colorectal tumors in mice and reduces lymphatic endothelial barrier integrity. PMID: 25754161
  80. Sod3 is a critical mediator of VEGF-C-induced breast cancer metastasis. PMID: 25358638
  81. VEGF-C mRNA accelerates hyperplasia of the lymphatic vessels induced by the tumor and plays an important role in lymph node metastasis in prostate cancer patients. PMID: 24858271
  82. No significant difference in VEGF-C levels was found in spondyloarthritis and Crohn's disease compared with controls. PMID: 25664492
  83. Neuropilin-2 mediates lymphangiogenesis of colorectal carcinoma via a VEGFC/VEGFR3 independent signaling. PMID: 25543087
  84. VEGF-c may play an important role in the development of endometrial cancer and its metastasis to retroperitoneal lymph node PMID: 23693075
  85. High expression of VEGFC is associated with the lymph node metastasis in squamous cell carcinomas of the uterine cervix. PMID: 24998585
  86. tumor cells that expressed high levels of SIX1 could promote lymphangiogenesis and counteract the negative effects of TGFbeta on lymphangiogenesis by increasing the expression of VEGF-C PMID: 25142796
  87. The genetic polymorphism of VEGF-C rs7664413 might be a predictive factor for the tumor size of urothelial cell carcinoma patients who have a smoking habit. PMID: 24608123
  88. Tbeta10 human recombinant proteins promoted the expression of VEGF-C by activating AKT phosphorylation in lung cancer cell lines. PMID: 24854554
  89. A truncating VEGFC mutation in a family with Milroy-like disease. PMID: 24744435
  90. VEGF-C down-regulates VEGFR-3 in lymphatic endothelial cells PMID: 25281926
  91. Radiation-induced activation of the PI3K/Akt/mTOR signaling pathway increases VEGF-C expression in lung cancer cells, thereby promoting endothelial cell proliferation. PMID: 24989178
  92. Genetic polymorphisms within VEGFC are associated with susceptibility to hepatocellular carcinoma. PMID: 24478168
  93. Increase of VEGFC protein expression is associated with oral squamous cell carcinoma. PMID: 24085575
  94. High VEGF-C expression is associated with bladder cancer. PMID: 24862180
  95. Mechanistic investigations showed that VEGF-C increased CTTN expression by downregulating Dicer-mediated maturation of miR326, thereby relieving the suppressive effect of miR326 on CTTN expression. PMID: 25205106
  96. Data suggest that VEGFC enhances cervical cancer invasiveness via up-regulation of galectin-3 via stimulation of NFkappaB/RELA pathway; galectin-3 interacts/activates VEGFR3 (vascular endothelial growth factor receptor-3). PMID: 24650367
  97. Coexpression of both PDGF-BB and VEGF-C was associated with lymphangiogenesis and poor prognosis in NSCLC. PMID: 24972450
  98. The present findings suggest the potential role of VEGF-C in the pathogenesis and development of a pterygium through lymphangiogenesis and the VEGF-C/VEGFR-3 pathway as a novel therapeutic target for the human pterygium. PMID: 22910845
  99. These findings suggest that the VEGFC/VEGFR3 pathway acts as an enhancer of ovarian cancer progression PMID: 24508126
  100. Increased expression of VEGF-C may play a significant role in the carcinogenesis and progression of gastric adenocarcinoma. PMID: 25076245

Show More

Hide All

Involvement in disease Lymphedema, hereditary, 1D (LMPH1D)
Subcellular Location Secreted
Protein Families PDGF/VEGF growth factor family
Tissue Specificity Spleen, lymph node, thymus, appendix, bone marrow, heart, placenta, ovary, skeletal muscle, prostate, testis, colon and small intestine and fetal liver, lung and kidney, but not in peripheral blood lymphocyte.
Database Links

HGNC: 12682

OMIM: 601528

KEGG: hsa:7424

STRING: 9606.ENSP00000280193

UniGene: Hs.435215

Most popular with customers

Newsletters

Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2020 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1